FR2389375B1 - - Google Patents

Info

Publication number
FR2389375B1
FR2389375B1 FR7813047A FR7813047A FR2389375B1 FR 2389375 B1 FR2389375 B1 FR 2389375B1 FR 7813047 A FR7813047 A FR 7813047A FR 7813047 A FR7813047 A FR 7813047A FR 2389375 B1 FR2389375 B1 FR 2389375B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7813047A
Other versions
FR2389375A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of FR2389375A1 publication Critical patent/FR2389375A1/fr
Application granted granted Critical
Publication of FR2389375B1 publication Critical patent/FR2389375B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR7813047A 1977-05-06 1978-05-03 Expired FR2389375B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5127877A JPS53136513A (en) 1977-05-06 1977-05-06 Stabilization of prostaglandin-x-related compounds

Publications (2)

Publication Number Publication Date
FR2389375A1 FR2389375A1 (fr) 1978-12-01
FR2389375B1 true FR2389375B1 (fr) 1982-08-06

Family

ID=12882465

Family Applications (2)

Application Number Title Priority Date Filing Date
FR7813047A Expired FR2389375B1 (fr) 1977-05-06 1978-05-03
FR7831038A Granted FR2398498A1 (fr) 1977-05-06 1978-11-02 Compositions stabilisees a usage pharmacologique contenant un analogue de la prostaglandine i2

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR7831038A Granted FR2398498A1 (fr) 1977-05-06 1978-11-02 Compositions stabilisees a usage pharmacologique contenant un analogue de la prostaglandine i2

Country Status (5)

Country Link
US (1) US4479944A (fr)
JP (1) JPS53136513A (fr)
DE (1) DE2819447A1 (fr)
FR (2) FR2389375B1 (fr)
GB (2) GB1604162A (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179141B (fr) * 1977-09-23 1982-08-28
DE2811950A1 (de) * 1978-03-18 1979-12-13 Hoechst Ag Neue analoga von prostacyclin
US4430340A (en) * 1978-07-17 1984-02-07 The Upjohn Company Stabilization of PGI2 compounds with surfactants
DE2902809A1 (de) 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
US4211793A (en) * 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
US4303671A (en) 1980-07-10 1981-12-01 The Upjohn Company Albumin stabilized prostacyclin
JPS6013779A (ja) * 1983-07-05 1985-01-24 Green Cross Corp:The プロスタグランジンｉ↓２誘導体
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
JP5925158B2 (ja) * 2013-06-04 2016-05-25 テックフィールズ バイオケム カンパニー リミテッド 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (fr) * 1970-06-10 1975-02-04
US3829579A (en) * 1971-11-01 1974-08-13 Upjohn Co Stable solutions of pge-type compounds
DE2357953A1 (de) * 1973-11-21 1975-05-28 Hoechst Ag Neue, natuerlich nicht vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
JPS51128948A (en) * 1975-10-20 1976-11-10 Ono Pharmaceut Co Ltd Prostaglandin analogues, process for preparing thereof and pharmaceuti cal compositions containing said analofues
IL51189A (en) * 1976-02-04 1985-08-30 Upjohn Co Prostaglandin analogs
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5395958A (en) * 1977-01-31 1978-08-22 Ono Pharmaceut Co Ltd Prostaglandin analogues and process for their preparation
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
HU179141B (fr) * 1977-09-23 1982-08-28
JPS54115368A (en) * 1978-03-01 1979-09-07 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent

Also Published As

Publication number Publication date
JPS53136513A (en) 1978-11-29
FR2398498B1 (fr) 1982-12-17
GB1604162A (en) 1981-12-02
US4479944A (en) 1984-10-30
GB1604161A (en) 1981-12-02
FR2398498A1 (fr) 1979-02-23
DE2819447A1 (de) 1978-11-09
FR2389375A1 (fr) 1978-12-01

Similar Documents

Publication Publication Date Title
FR2398498B1 (fr)
AU3353778A (fr)
FR2377428B1 (fr)
AU71461S (fr)
BG25819A1 (fr)
BG25860A1 (fr)
BE868323A (fr)
BE870787A (fr)
BE871419A (fr)
BE865722A (fr)
BE872973A (fr)
BE873002A (fr)
BG23438A1 (fr)
BG23462A1 (fr)
BG24331A1 (fr)
BG24713A1 (fr)
BG25808A1 (fr)
BG25809A1 (fr)
BG25810A1 (fr)
BG25811A1 (fr)
BG25823A1 (fr)
BG25813A1 (fr)
BG25815A1 (fr)
BE851449A (fr)
BG25820A1 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse